文献速递类风湿关节炎

阿司匹林在类风湿关节炎一级心血管预防中的潜在获益:PRECISION 试验的二次分析

The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

该研究为 PRECISION 试验的二次分析,纳入 1852 例无已知心血管病的类风湿关节炎患者,其中 540 例报告使用低剂量阿司匹林进行心血管预防,1312 例未使用。结果显示,使用阿司匹林者与未使用者的主要 NSAID 毒性风险相似(HR=1.08,95%CI:0.69,1.69),主要不良心血管事件风险也相似(HR=1.23,95%CI:0.72,2.10)。

要点

  • 在无已知心血管病的 RA 患者中,低剂量阿司匹林使用者与未使用者的主要 NSAID 毒性风险相似(HR=1.08,95%CI:0.69,1.69)。
  • 主要不良心血管事件风险在年龄和性别调整模型中两组也相似(HR=1.23,95%CI:0.72,2.10)。
  • 使用低剂量阿司匹林合并慢性 NSAIDs 和埃索美拉唑的 RA 患者,其风险与未使用者相似。

核心结论

  • 使用低剂量阿司匹林并同时接受慢性 NSAIDs 和埃索美拉唑治疗的 RA 患者,其主要 NSAID 毒性和 MACE 风险与未使用者相似。

研究设计与样本

  • 本研究为 PRECISION 试验的二次分析,采用队列研究设计,纳入无已知心血管病的 RA 患者,使用 Cox 回归估计发病率比和风险比。
  • 共纳入 1852 例无已知心血管病的 RA 患者,其中 540 例报告使用低剂量阿司匹林进行心血管预防,1312 例未使用。
  • 所有入组患者均接受开放标签的埃索美拉唑。

主要发现

  • 主要复合结局(主要 NSAID 毒性,包括 MACE、临床显著胃肠道事件、肾脏事件和全因死亡)在非阿司匹林使用者中观察到 79 例(6.0%),在阿司匹林使用者中观察到 37 例(6.9%),P=0.50。
  • 阿司匹林使用者经历主要结局各组成部分的比例与未使用者相似。
  • 在完全调整模型中,阿司匹林暴露组间主要 NSAID 毒性风险相似(HR=1.08,95%CI:0.69,1.69)。
  • 在年龄和性别调整模型中,暴露组间 MACE 风险也相似(HR=1.23,95%CI:0.72,2.10)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Guidelines exist for the use of low-dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit considerations may differ in RA. While RA confers an increased CV risk, such patients more likely use NSAIDs and corticosteroids. METHODS: We conducted a cohort study to assess potential risks and benefits of low-dose aspirin. We estimated incidence rates and hazard ratios (HRs) using Cox regression among subjects with RA but no known CV disease in the Prospective Randomized Evaluation of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen trial. The primary exposure of interest was low-dose aspirin, and all enrolled patients were provided open-label esomeprazole. The primary composite outcome was major NSAID toxicity, including major adverse CV event (MACE), clinically significant gastrointestinal events, renal events and all-cause mortality. RESULTS: We found 1852 subjects with RA in Prospective Randomized Evaluation of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen without known CV disease; 540 reported using low-dose aspirin for CV prevention and 1312 did not. Any major NSAID toxicity was observed in 79 (6.0%) non-aspirin users and 37 (6.9%) aspirin users (P = 0.50). Aspirin users experienced all components of the primary outcome at a similar rate to non-users. In fully adjusted models, the risk for major NSAID toxicity was similar between aspirin exposure groups (HR = 1.08, 95% CI: 0.69, 1.69). The risk for MACE was also similar between exposure groups in age- and gender-adjusted models (HR = 1.23, 95% CI: 0.72, 2.10). CONCLUSION: RA patients using low-dose aspirin with chronic NSAIDs and esomeprazole had a similar risk of major NSAID toxicity and MACE as patients who did not.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Solomon DH, Libby P, Yeomans ND, et al. The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. Rheumatology (Oxford). 2018. PMID: 29688503. doi:10.1093/rheumatology/key105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。